Skip to main content

Zeynep Eroglu



Moffitt Cancer Center, Tampa, FL, USA

Latest contributions from Zeynep Eroglu

28-01-2019 | Melanoma | Editorial | Article

IDO inhibitors in advanced melanoma: A path forward?

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.